Biora Total Revenue vs Net Interest Income Analysis

BIOR Stock

USD 1.67 0.04 2.45%

Biora Therapeutics financial indicator trend analysis is way more than just evaluating Biora Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biora Therapeutics is a good investment. Please check the relationship between Biora Therapeutics Total Revenue and its Net Interest Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biora Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Biora Stock, please use our How to Invest in Biora Therapeutics guide.

Total Revenue vs Net Interest Income

Total Revenue vs Net Interest Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biora Therapeutics Total Revenue account and Net Interest Income. At this time, the significance of the direction appears to have weak relationship.

The correlation between Biora Therapeutics' Total Revenue and Net Interest Income is 0.33. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Net Interest Income in the same time period over historical financial statements of Biora Therapeutics, assuming nothing else is changed. The correlation between historical values of Biora Therapeutics' Total Revenue and Net Interest Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Biora Therapeutics are associated (or correlated) with its Net Interest Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Interest Income has no effect on the direction of Total Revenue i.e., Biora Therapeutics' Total Revenue and Net Interest Income go up and down completely randomly.

Correlation Coefficient

0.33

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Total Revenue

Total revenue comprises all receipts Biora Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.

Most indicators from Biora Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biora Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biora Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Biora Stock, please use our How to Invest in Biora Therapeutics guide.At this time, Biora Therapeutics' Tax Provision is relatively stable compared to the past year. As of 11/24/2024, Selling General Administrative is likely to grow to about 44.4 M, while Issuance Of Capital Stock is likely to drop slightly above 14.8 M.

	2021	2022	2023	2024 (projected)
Interest Expense	12.6M	11.0M	9.8M	11.5M
Depreciation And Amortization	1.4M	907K	555K	527.3K

Interest Expense Depreciation And Amortization

Biora Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity
Total Assets		0.4	-0.35	0.61	0.56	0.26	0.29	0.86	0.53	-0.36	0.76	0.9	0.8	0.75	-0.54	0.44	0.24	0.92	0.47	0.84	-0.92	0.02	0.04	0.8	0.1	-0.69
Short Long Term Debt Total	0.4		0.41	-0.32	-0.39	0.65	-0.58	0.02	-0.45	0.63	-0.19	0.34	0.74	-0.1	0.01	0.71	0.95	0.48	-0.16	0.38	-0.25	0.81	-0.62	0.19	0.87	0.29
Other Current Liab	-0.35	0.41		-0.43	-0.82	0.55	-0.78	-0.62	-0.9	0.47	-0.83	-0.31	0.19	-0.72	0.79	0.48	0.5	-0.17	-0.57	-0.53	0.64	0.67	-0.75	-0.41	0.78	0.85
Total Current Liabilities	0.61	-0.32	-0.43		0.55	0.06	0.37	0.78	0.77	-0.74	0.7	0.76	0.2	0.7	-0.36	0.03	-0.43	0.37	0.81	0.45	-0.59	-0.47	0.23	0.74	-0.4	-0.7
Total Stockholder Equity	0.56	-0.39	-0.82	0.55		-0.59	0.95	0.68	0.85	-0.79	0.92	0.36	0.12	0.7	-0.57	-0.39	-0.54	0.52	0.35	0.6	-0.73	-0.73	0.73	0.37	-0.71	-0.89
Other Liab	0.26	0.65	0.55	0.06	-0.59		-0.75	0.16	-0.39	0.52	-0.28	0.47	0.43	0.07	-0.01	0.93	0.68	0.14	0.15	0.02	0.03	0.77	-0.63	0.47	0.8	0.28
Net Tangible Assets	0.29	-0.58	-0.78	0.37	0.95	-0.75		0.47	0.74	-0.78	0.78	0.07	-0.13	0.54	-0.47	-0.54	-0.68	0.3	0.15	0.36	-0.48	-0.82	0.84	0.13	-0.82	-0.78
Property Plant And Equipment Net	0.86	0.02	-0.62	0.78	0.68	0.16	0.47		0.79	-0.49	0.9	0.89	0.4	0.97	-0.79	0.28	-0.13	0.63	0.71	0.74	-0.85	-0.27	0.38	0.93	-0.26	-0.88
Current Deferred Revenue	0.53	-0.45	-0.9	0.77	0.85	-0.39	0.74	0.79		-0.71	0.92	0.56	-0.04	0.81	-0.69	-0.36	-0.59	0.29	0.77	0.61	-0.73	-0.74	0.66	0.61	-0.75	-0.91
Net Debt	-0.36	0.63	0.47	-0.74	-0.79	0.52	-0.78	-0.49	-0.71		-0.67	-0.27	-0.03	-0.45	0.12	0.41	0.74	-0.34	-0.33	-0.27	0.42	0.79	-0.52	-0.24	0.7	0.66
Retained Earnings	0.76	-0.19	-0.83	0.7	0.92	-0.28	0.78	0.9	0.92	-0.67		0.67	0.25	0.9	-0.77	-0.11	-0.37	0.6	0.61	0.77	-0.88	-0.57	0.63	0.7	-0.55	-0.97
Accounts Payable	0.9	0.34	-0.31	0.76	0.36	0.47	0.07	0.89	0.56	-0.27	0.67		0.63	0.78	-0.56	0.5	0.2	0.68	0.74	0.74	-0.81	0.06	-0.06	0.94	0.11	-0.63
Cash	0.8	0.74	0.19	0.2	0.12	0.43	-0.13	0.4	-0.04	-0.03	0.25	0.63		0.22	-0.02	0.6	0.64	0.91	0.01	0.58	-0.6	0.46	-0.46	0.4	0.58	-0.16
Non Current Assets Total	0.75	-0.1	-0.72	0.7	0.7	0.07	0.54	0.97	0.81	-0.45	0.9	0.78	0.22		-0.89	0.2	-0.21	0.49	0.69	0.65	-0.77	-0.33	0.51	0.89	-0.37	-0.92
Non Currrent Assets Other	-0.54	0.01	0.79	-0.36	-0.57	-0.01	-0.47	-0.79	-0.69	0.12	-0.77	-0.56	-0.02	-0.89		-0.11	0.1	-0.28	-0.57	-0.61	0.66	0.24	-0.58	-0.73	0.35	0.79
Other Assets	0.44	0.71	0.48	0.03	-0.39	0.93	-0.54	0.28	-0.36	0.41	-0.11	0.5	0.6	0.2	-0.11		0.71	0.39	-0.01	0.13	-0.1	0.75	-0.51	0.5	0.79	0.12
Long Term Debt	0.24	0.95	0.5	-0.43	-0.54	0.68	-0.68	-0.13	-0.59	0.74	-0.37	0.2	0.64	-0.21	0.1	0.71		0.34	-0.27	0.13	-0.06	0.94	-0.75	0.07	0.92	0.39
Cash And Short Term Investments	0.92	0.48	-0.17	0.37	0.52	0.14	0.3	0.63	0.29	-0.34	0.6	0.68	0.91	0.49	-0.28	0.39	0.34		0.12	0.73	-0.8	0.11	-0.08	0.51	0.21	-0.52
Net Receivables	0.47	-0.16	-0.57	0.81	0.35	0.15	0.15	0.71	0.77	-0.33	0.61	0.74	0.01	0.69	-0.57	-0.01	-0.27	0.12		0.52	-0.58	-0.34	0.21	0.78	-0.36	-0.61
Good Will	0.84	0.38	-0.53	0.45	0.6	0.02	0.36	0.74	0.61	-0.27	0.77	0.74	0.58	0.65	-0.61	0.13	0.13	0.73	0.52		-0.95	-0.19	0.27	0.65	-0.07	-0.61
Common Stock Shares Outstanding	-0.92	-0.25	0.64	-0.59	-0.73	0.03	-0.48	-0.85	-0.73	0.42	-0.88	-0.81	-0.6	-0.77	0.66	-0.1	-0.06	-0.8	-0.58	-0.95		0.23	-0.27	-0.72	0.17	0.79
Non Current Liabilities Total	0.02	0.81	0.67	-0.47	-0.73	0.77	-0.82	-0.27	-0.74	0.79	-0.57	0.06	0.46	-0.33	0.24	0.75	0.94	0.11	-0.34	-0.19	0.23		-0.83	-0.02	0.94	0.54
Capital Lease Obligations	0.04	-0.62	-0.75	0.23	0.73	-0.63	0.84	0.38	0.66	-0.52	0.63	-0.06	-0.46	0.51	-0.58	-0.51	-0.75	-0.08	0.21	0.27	-0.27	-0.83		0.14	-0.82	-0.61
Inventory	0.8	0.19	-0.41	0.74	0.37	0.47	0.13	0.93	0.61	-0.24	0.7	0.94	0.4	0.89	-0.73	0.5	0.07	0.51	0.78	0.65	-0.72	-0.02	0.14		-0.01	-0.68
Other Current Assets	0.1	0.87	0.78	-0.4	-0.71	0.8	-0.82	-0.26	-0.75	0.7	-0.55	0.11	0.58	-0.37	0.35	0.79	0.92	0.21	-0.36	-0.07	0.17	0.94	-0.82	-0.01		0.6
Other Stockholder Equity	-0.69	0.29	0.85	-0.7	-0.89	0.28	-0.78	-0.88	-0.91	0.66	-0.97	-0.63	-0.16	-0.92	0.79	0.12	0.39	-0.52	-0.61	-0.61	0.79	0.54	-0.61	-0.68	0.6

Click cells to compare fundamentals

Biora Therapeutics Account Relationship Matchups

Biora Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	101.7M	154.4M	108.8M	53.5M	31.2M	29.7M
Short Long Term Debt Total	73.4M	162.3M	126.4M	127.8M	47.4M	45.1M
Other Current Liab	6.0M	54.6M	52.6M	18.8M	56.7M	35.5M
Total Current Liabilities	100.3M	72.7M	61.6M	23.3M	63.0M	53.2M
Total Stockholder Equity	(83.9M)	(107.0M)	(85.0M)	(102.3M)	(101.4M)	(106.5M)
Property Plant And Equipment Net	15.9M	17.8M	4.0M	3.1M	2.8M	2.6M
Current Deferred Revenue	77.6M	378K	301K	47K	542K	514.9K
Net Debt	40.3M	70.2M	38.0M	97.3M	32.2M	55.3M
Retained Earnings	(348.5M)	(541.3M)	(788.7M)	(826.8M)	(951.0M)	(998.5M)
Accounts Payable	15.8M	17.4M	8.7M	3.6M	2.8M	2.7M
Cash	33.0M	92.1M	88.4M	30.5M	15.2M	14.5M
Non Current Assets Total	27.1M	28.1M	10.4M	15.4M	12.1M	16.1M
Other Assets	198K	13.9M	326K	1.0	0.9	0.86
Long Term Debt	72.0M	161.7M	126.4M	127.8M	43.7M	80.3M
Cash And Short Term Investments	33.0M	92.1M	88.4M	30.5M	15.2M	14.5M
Net Receivables	22.8M	6.6M	653K	828K	830K	788.5K
Common Stock Shares Outstanding	1.8M	2.2M	3.8M	7.6M	15.8M	16.6M
Liabilities And Stockholders Equity	101.7M	154.4M	108.8M	53.5M	31.2M	29.7M
Non Current Liabilities Total	85.3M	188.8M	132.2M	132.5M	69.7M	125.3M
Capital Lease Obligations	1.1M	358K	12K	1.5M	1.7M	873.9K
Inventory	10.9M	12.2M	2.1M	2.6M	2.3M	2.2M
Other Current Assets	1.4M	15.4M	9.4M	6.8M	3.0M	2.9M
Other Stockholder Equity	264.6M	434.2M	703.6M	724.5M	849.5M	565.0M
Total Liab	185.6M	261.4M	193.8M	155.8M	132.6M	144.4M
Net Invested Capital	(11.6M)	55.0M	41.4M	25.5M	(55.7M)	(52.9M)
Short Long Term Debt	241K	271K	12K	2.0M	2.3M	2.4M
Total Current Assets	74.6M	126.3M	98.4M	38.1M	19.1M	18.1M
Capital Stock	38K	59K	146K	8K	25K	40.5K
Non Current Liabilities Other	654K	1.6M	5.6M	4.1M	2.2M	2.7M
Net Working Capital	(25.7M)	53.7M	36.8M	14.8M	(43.9M)	(41.7M)
Short Term Debt	968K	338K	24K	893K	2.9M	3.0M

Pair Trading with Biora Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biora Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biora Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Biora Stock

0.61	A	Agilent Technologies Earnings Call Tomorrow	Pair Corr
0.85	ME	23Andme Holding	Pair Corr
0.83	VALN	Valneva SE ADR	Pair Corr
0.85	JNJ	Johnson Johnson Sell-off Trend	Pair Corr

Moving against Biora Stock

0.65	MDGL	Madrigal Pharmaceuticals	Pair Corr
0.5	KZR	Kezar Life Sciences	Pair Corr
0.44	RNXT	RenovoRx	Pair Corr
0.41	MLYS	Mineralys Therapeutics,	Pair Corr

The ability to find closely correlated positions to Biora Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biora Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biora Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biora Therapeutics to buy it.

The correlation of Biora Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biora Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biora Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Biora Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Biora Stock Analysis

When running Biora Therapeutics' price analysis, check to measure Biora Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biora Therapeutics is operating at the current time. Most of Biora Therapeutics' value examination focuses on studying past and present price action to predict the probability of Biora Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biora Therapeutics' price. Additionally, you may evaluate how the addition of Biora Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC